Surya Pharmaceutical Ltd, the flagship company of Rs 1,700-crore Surya Corp, has closed two of its units namely Jammu plant, which was still under trial production and one at Panchkula (Haryana) unit.
Chandigarh-based Surya Pharmaceutical Ltd(listed on BSE, NSE), the flagship company of Rs 1600 crore, Surya Corp is planning to set up a fully integrated unit comprising API’s and formulation in Punjab with an investment of Rs 1000 crore.
Chandigarh-based Surya Pharmaceutical Ltd, a premier integrated pharmaceutical company in India, has acquired ActivOn, a leading OTC analgesic drug brand in the USA, with global marketing rights.
Chandigarh-based Surya Pharmaceutical is regarded as a star performer in the Indian drug industry, which is growing at close to 20 per cent every year.
Surya Pharmaceutical is trading higher by 2% at Rs 337 after the board recommended a sub-division of the fully paid equity shares of Rs 10 each to fully paid equity shares of Re 1 each.
Surya Pharma is trading at a lifetime high, up 10% at Rs 205 after the company posted a 74% jump in net profit to Rs 23.34 crore for the quarter ended June 2010 against Rs 13.37 crore during the same quarter of the previous year.
Chandigarh-based Surya Pharmaceutical Ltd is planning to raise Rs 500 crore through various instrument like Rights Issue, Global Depository Receipts (GDRs), American Depository Receipts (ADRs), Foreign Currency Convertible Bonds (FCCBs) and External
Chandigarh-based Surya Pharmaceutical Limited plans to set up over 500 healthcare and pharma retail stores under the brand Viva in the next three years.
